Pfizer introduces a new HER2-negative breast cancer targeted treatment
A targeted therapy for HER2-negative patients is expected to be introduced in the domestic market.
According to the industry concerned on the 7th, Pfizer Pharmaceuticals Korea has recently turned in an approval application of ‘Ibrance(palbociclib),’ a breast cancer treatment. Considering the usu...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
